Nevertheless, single drugs that rely solely on STING agonists, such as cyclic dinucleotide (CDN), are not significantly effective in two phase I clinical trials against solid tumors or lymphomas [17], which could attribute to rapid clearance and poor internalization of STING agonists [18] and immunosuppression of excessive STING agonists [19]. This evidence concerns the gene STING1 and lymphoma.